Luciano Santollani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Luciano Santollani has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Elizabeth Fink
Department of Chemical Engineering, Massachusetts Institute of Technology; Cambridge, MA, USA
21 shared publications - Jordan A. Stinson
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts
21 shared publications - Joseph R. Palmeri
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA
21 shared publications - Lauren Duhamel
Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
21 shared publications - Allison Sheen
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts
20 shared publications - Brianna Marie Lax
Technical University of Denmark Søltofts Plads 220
20 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control
Characterization of recombinant glucose oxidase fusions
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control
Characterization of recombinant glucose oxidase fusions
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control
Fluorescence intensities of OT-I phenotypic markers from the cross-presentation assay with IFNa
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control
Fluorescence intensities of OT-I phenotypic markers from the cross-presentation assay with IFNa
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control
2.5F-GOX and MSA-IFNa do not cause toxicity in mice but fail to generate anti-tumor memory
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control
2.5F-GOX and MSA-IFNa do not cause toxicity in mice but fail to generate anti-tumor memory
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control
Cross-presentation assay myeloid cell gating strategy
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control
Cross-presentation assay myeloid cell gating strategy
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control
Cross-presentation assay T-cell gating strategy
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control
Cross-presentation assay T-cell gating strategy
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control
Comparison of OT-I phenotypes in cross-presentation assay after treatment with immunogenic cell stress-inducing chemotherapy
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control
Comparison of OT-I phenotypes in cross-presentation assay after treatment with immunogenic cell stress-inducing chemotherapy
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control
Additional flow analysis of 2.5F-GOX dose escalation study
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control
Additional flow analysis of 2.5F-GOX dose escalation study
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control
Bolus hydrogen peroxide is cytotoxic but rapidly cleared by cancer cells
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control
Bolus hydrogen peroxide is cytotoxic but rapidly cleared by cancer cells
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control
Although heightened intratumoral levels of reactive oxygen species (ROS) are typically associated with a suppressive tumor microenvironment, under certain conditions ROS contribute to tumor elimination. Treatment approaches, including some chemotherapy and radiation protocols, increase cancer cell ROS levels that influence their mechanism of cell death and subsequent recognition by the immune system. Furthermore, activated myeloid cells rapidly generate ROS upon encounter with pathogens or infected cells to eliminate disease, and recently, this effector function has been noted in cancer contexts as well. Collectively, ROS-induced cancer cell death may help initiate adaptive antitumor immune responses that could synergize with current approved immunotherapies, for improved control of solid tumors. In this work, we explore the use of glucose oxidase, an enzyme which produces hydrogen peroxide, a type of ROS, to therapeutically mimic the endogenous oxidative burst from myeloid cells to promote antigen generation within the tumor microenvironment. We engineer the enzyme to target pan-tumor-expressed integrins both as a tumor-agnostic therapeutic approach and as a strategy to prolong local enzyme activity following intratumoral administration. We found the targeted enzyme potently induced cancer cell death and enhanced cross-presentation by dendritic cells in vitro and further combined with interferon alpha for long-term tumor control in murine MC38 tumors in vivo. Optimizing the single-dose administration of this enzyme overcomes limitations with immunogenicity noted for other prooxidant enzyme approaches. Overall, our results suggest ROS-induced cell death can be harnessed for tumor control and highlight the potential use of designed enzyme therapies alongside immunotherapy against cancer.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control
Although heightened intratumoral levels of reactive oxygen species (ROS) are typically associated with a suppressive tumor microenvironment, under certain conditions ROS contribute to tumor elimination. Treatment approaches, including some chemotherapy and radiation protocols, increase cancer cell ROS levels that influence their mechanism of cell death and subsequent recognition by the immune system. Furthermore, activated myeloid cells rapidly generate ROS upon encounter with pathogens or infected cells to eliminate disease, and recently, this effector function has been noted in cancer contexts as well. Collectively, ROS-induced cancer cell death may help initiate adaptive antitumor immune responses that could synergize with current approved immunotherapies, for improved control of solid tumors. In this work, we explore the use of glucose oxidase, an enzyme which produces hydrogen peroxide, a type of ROS, to therapeutically mimic the endogenous oxidative burst from myeloid cells to promote antigen generation within the tumor microenvironment. We engineer the enzyme to target pan-tumor-expressed integrins both as a tumor-agnostic therapeutic approach and as a strategy to prolong local enzyme activity following intratumoral administration. We found the targeted enzyme potently induced cancer cell death and enhanced cross-presentation by dendritic cells in vitro and further combined with interferon alpha for long-term tumor control in murine MC38 tumors in vivo. Optimizing the single-dose administration of this enzyme overcomes limitations with immunogenicity noted for other prooxidant enzyme approaches. Overall, our results suggest ROS-induced cell death can be harnessed for tumor control and highlight the potential use of designed enzyme therapies alongside immunotherapy against cancer.